




RealRate

PHARMACEUTICAL 2012

Ernexa Therapeutics Inc
Rank 103 of 196



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 111% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	2,798
Cost of Goods Sold	0
Intangible Assets	2,081
Liabilities, Current	3,868
Liabilities, Non-Current	323
Other Assets	2,513
Other Compr. Net Income	-223
Other Expenses	6,698
Other Liabilities	1,106
Other Net Income	20
Other Revenues	23,870
Property and Equipment	4,255
Research and Development	0
Selling, General and Administrative Expense	20,448

Output Variable	Value in 1000 USD
Assets	11,647
Liabilities	5,297
Expenses	27,146
Revenues	23,870
Stockholders Equity	6,350
Net Income	-3,256
Comprehensive Net Income	-3,368
BaseVar	34,102
ECR before Limited Liability	124%
Economic Capital Ratio	248%